BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN ... The company said new data from a study in Japan showed strong treatment adherence with VOXZOGO in children with achondroplasia under the age ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...